Equities analysts expect that Endo International PLC (NASDAQ:ENDP) (TSE:ENL) will report $780.75 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for Endo International PLC’s earnings, with estimates ranging from $763.87 million to $802.00 million. Endo International PLC reported sales of $884.34 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 11.7%. The firm is expected to report its next quarterly earnings results on Tuesday, November 14th.

On average, analysts expect that Endo International PLC will report full year sales of $780.75 million for the current year, with estimates ranging from $3.43 billion to $3.60 billion. For the next fiscal year, analysts expect that the company will post sales of $3.21 billion per share, with estimates ranging from $2.91 billion to $3.45 billion. Zacks’ sales averages are a mean average based on a survey of research firms that cover Endo International PLC.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last issued its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, topping the consensus estimate of $0.74 by $0.19. Endo International PLC had a negative net margin of 126.93% and a positive return on equity of 37.58%. The firm had revenue of $875.73 million for the quarter, compared to analysts’ expectations of $832.66 million. During the same period in the previous year, the firm posted $0.86 EPS. The company’s revenue for the quarter was down 4.9% on a year-over-year basis.

A number of research analysts recently weighed in on ENDP shares. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. Mizuho reaffirmed a “buy” rating and set a $14.00 price objective (down from $19.00) on shares of Endo International PLC in a research note on Tuesday. William Blair reaffirmed a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Zacks Investment Research lowered shares of Endo International PLC from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Finally, Canaccord Genuity set a $14.00 price objective on shares of Endo International PLC and gave the stock a “hold” rating in a research note on Monday, May 22nd. Three investment analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $14.49.

Endo International PLC (NASDAQ ENDP) opened at 8.62 on Friday. Endo International PLC has a 52 week low of $7.41 and a 52 week high of $23.98. The company has a 50-day moving average of $8.95 and a 200-day moving average of $10.92. The firm’s market cap is $1.93 billion.

COPYRIGHT VIOLATION NOTICE: “Zacks: Analysts Anticipate Endo International PLC (ENDP) Will Post Quarterly Sales of $780.75 Million” was published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/15/zacks-analysts-anticipate-endo-international-plc-endp-will-post-quarterly-sales-of-780-75-million.html.

In other news, CFO Blaise Coleman bought 6,500 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were purchased at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the transaction, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Terrance J. Coughlin bought 20,000 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average price of $7.70 per share, for a total transaction of $154,000.00. Following the transaction, the chief operating officer now owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The disclosure for this purchase can be found here. Insiders have bought 36,000 shares of company stock worth $279,460 in the last 90 days. Insiders own 0.50% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of ENDP. OppenheimerFunds Inc. lifted its holdings in Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after acquiring an additional 1,857,678 shares during the period. Bank of New York Mellon Corp lifted its holdings in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after acquiring an additional 633,904 shares during the period. Teachers Advisors LLC lifted its holdings in Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after acquiring an additional 15,928 shares during the period. TIAA CREF Investment Management LLC lifted its holdings in Endo International PLC by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after acquiring an additional 10,387 shares during the period. Finally, Schneider Capital Management Corp lifted its holdings in Endo International PLC by 14.9% in the first quarter. Schneider Capital Management Corp now owns 642,311 shares of the company’s stock valued at $7,168,000 after acquiring an additional 83,100 shares during the period. Hedge funds and other institutional investors own 90.74% of the company’s stock.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International PLC (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.